周産期心筋症診療の手引き

書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

本書は,心疾患を指摘されていなかった妊産婦が突然心不全を発症する「周産期心筋症」をなるべく早期に診断・治療するため,日本産科婦人科学会、日本新心不全学会の評価,賛同のもと作成された.産期心筋症は本邦では稀な疾患だが,妊産婦の高齢化などの要因により,今後増加していく可能性がある.産婦の心不全症状の初診医の3/4を占める産科医・総合医にもその疾患概念を広く周知し,診療の質を向上させる一歩となる一冊.

目次

  • 第I章　序文

    第II章　診断基準

    第III章　疫学
    　1．発症率
    　2．日本における疫学
    　3．発症率に関する先行研究の問題点

    第IV章　リスク因子
    　SECTION　1　妊娠高血圧症候群
    　　1．定義と臨床分類について
    　　2．病態
    　　3．妊娠高血圧症候群と周産期心筋症
    　　4．周産期心筋症とsFlt-1
    　SECTION　2　多胎
    　　1．疫学的要素
    　　2．生理的変化
    　　3．妊娠高血圧症候群
    　　4．切迫早産
    　　5．帝王切開分娩
    　SECTION　3　切迫早産治療
    　SECTION　4　高年妊娠
    　　1．出産年齢と周産期心筋症発症の関係
    　　2．出産年齢と周産期心筋症経過・予後との関係
    　　3．出産年齢の高齢化との関係

    第V章　病因
    　SECTION　1　血管機能障害
    　　1．用語解説
    　　2．正常妊娠における血管内皮機能変化
    　　3．正常妊娠における血管機能の変化
    　　4．妊娠高血圧症候群における血管機能指標の変化
    　　5．妊娠高血圧腎症の女性における産後微小血管障害の病態とは
    　SECTION　2　遺伝性心筋症
    　SECTION　3　血管障害因子とそのほか
    　　1．血管障害因子説
    　　2．ウイルス性心筋炎説
    　　3．妊娠に対する異常な免疫反応説
    　　4．妊娠による心負荷への反応説

    第VI章　生理・画像検査
    　SECTION　1　心エコー検査
    　　1．正常な妊娠中の心エコーの変化
    　　2．心エコーの適応
    　　3．心エコーによる左室収縮能評価
    　　4．予後と心エコー
    　　5．合併症と心エコー
    　SECTION　2　心電図
    　　1．周産期心筋症における心電図所見
    　　2．心電図所見と周産期心筋症患者の予後
    　SECTION　3　MRI
    　　1．周産期心筋症の診断
    　　2．心臓MR
    　　3．周産期におけるMRI検査の安全性について
    　　4．周産期心筋症患者におけるCMRの役割

    第VII章　病理組織学的診断

    第VIII章　妊産婦における症状・身体所見の診方と検査の進め方
    　1．妊娠・産後経過における症状・身体所見
    　2．検査の進め方

    第IX章　鑑別診断
    　1．妊娠関連急性心筋梗塞
    　2．肺血栓塞栓症
    　3．心筋炎
    　4．後天的な要因による心筋症

    第X章　遺伝学的検査
    　1．拡張型心筋症関連遺伝子の関与
    　2．妊娠高血圧症候群関連遺伝子の関与

    第Ⅺ章　治療
    　SECTION　1　心不全治療
    　　1．周産期心筋症における心不全治療
    　　2．周産期心筋症を疑った場合に施行する検査
    　　3．初期治療
    　　4．薬物療法
    　　5．非薬物的治療
    　　6．その他の注意事項
    　SECTION　2　疾患特異的治療

    第Ⅻ章　予後
    　SECTION　1　心機能予後
    　　1．死亡率
    　　2．心機能回復の頻度
    　　3．心機能回復の予測因子
    　　4．妊娠高血圧と予後の関係
    　　5．拡張型心筋症とのオーバーラップと予後について
    　SECTION　2　次回妊娠予後
    　　1．母体予後
    　　2．胎児予後
    　　3．次回妊娠に関するカウンセリング
    　　4．避妊方法

    付記1　ハイリスク妊娠における早期診断法
    付記2　周産期心筋症　症例集

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第I章 序文

P.2 掲載の参考文献
1) Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971 ; 44 : 964-8.
PubMed
2) Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation. 2005 ; 111 : 2050-5.
 
3) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
4) 石渡勇, 池田智明. 日本の妊産婦を救うために 2015. 東京 : 東京医学社 ; 2015. p. 28-34.
 
5) Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000 ; 283 : 1183-8.
PubMed
6) Ruys TP, Roos-Hesselink JW, Hau R, et al. Heart failure in pregnant women with cardiac disease : data from the ROPAC. Heart. 2014 ; 100 : 231-8.
 
7) Bernstein PS, Magriples U. Cardiomyopathy in pregnancy : a retrospective study. Am J Perinatol. 2001 ; 18 : 163-8.
PubMed
8) Ware JS, Li J, Mazaika E, et al. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016 ; 374 : 233-41.
PubMed

第II章 診断基準

P.4 掲載の参考文献
1) Hull E, Hafkesbring E. Toxic postpartal heart disease. New Orleans M. & S. J. 1937 ; 89 : 550.
 
2) Meadows WR. Idiopathic myocardial failure in the last trimester of pregnancy and the puerperium. Circulation. 1957 ; 15 : 903-14.
PubMed
3) Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971 ; 44 : 964-8.
PubMed
4) Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000 ; 283 : 1183-8.
PubMed
5) Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation. 2005 : 111 : 2050-5.
 
6) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-78.
 

第III章 疫学

P.9 掲載の参考文献
1) Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States : a nationwide population-based study. J Am Heart Assoc. 2014 ; 3 : e001056.
PubMed
2) Afana M, Brinjikji W, Kao D, et al. Characteristics and in-hospital outcomes of peripartum cardiomyopathy diagnosed during delivery in the United States from the Nationwide Inpatient Sample (NIS) database. J Card Fail. 2016 ; 22 : 512-9.
PubMed
3) Krishnamoorthy P, Garg J, Palaniswamy C, et al. Epidemiology and outcomes of peripartum cardiomyopathy in the United States : findings from the Nationwide Inpatient Sample. J Cardiovasc Med. 2016 ; 17 : 756-61.
 
4) Kuklina EV, Callaghan WM. Cardiomyopathy and other myocardial disorders among hospitalizations for pregnancy in the United States : 2004-2006. Obstet Gynecol. 2010 ; 115 : 93-100.
PubMed
5) Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006 ; 97 : 1765-8.
PubMed
6) Kao DP, Hsich E, Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart failure. 2013 ; 1 : 409-16.
PubMed
7) Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007 ; 100 : 302-4.
PubMed
8) Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy : incidence, predictors, and outcomes. Obstet Gynecol. 2011 ; 118 : 583-91.
PubMed
9) Harper MA, Meyer RE, Berg CJ. Peripartum cardiomyopathy : population-based birth prevalence and 7-year mortality. Obstet Gynecol. 2012 ; 120 : 1013-9.
PubMed
10) Chapa JB, Heiberger HB, Weinert L, et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol. 2005 ; 105 : 1303-8.
PubMed
11) Ford RF, Barton JR, O'Brien JM, et al. Demographics, management, and outcome of peripartum cardiomyopathy in a community hospital. Am J Obstet Gynecol. 2000 ; 182 : 1036-8.
 
12) Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy : an ominous diagnosis. Am J Obstet Gynecol. 1997 ; 176 : 182-8.
PubMed
13) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
14) Lee S, Cho GJ, Park GU, et al. Incidence, risk factors, and clinical characteristics of peripartum cardiomyopathy in South Korea. Circ Heart Fail. 2018 ; 11 : e004134.
 
15) Wu VC, Chen TH, Yeh JK, et al. Clinical outcomes of peripartum cardiomyopathy : a 15-year nationwide population-based study in Asia. Medicine. 2017 ; 96 : e8374.
PubMed
16) Lim CP, Sim DK. Peripartum cardiomyopathy : experience in an Asian tertiary centre. Singapore Med J. 2013 ; 54 : 24-7.
 
17) Samonte VI, Ngalob QG, Mata GD, et al. Clinical and echocardiographic profile and outcomes of peripartum cardiomyopathy : the Philippine General Hospital experience. Heart Asia. 2013 ; 5 : 245-9.
PubMed
18) Hasan JA, Qureshi A, Ramejo BB, et al. Peripartum cardiomyopathy characteristics and outcome in a tertiary care hospital. J Pak Med Assoc. 2010 ; 60 : 377-80.
 
19) Liu H, Xu JW, Zhao XD, et al. Pregnancy outcomes in women with heart disease. Chin Med J. 2010 ; 123 : 2324-30.
PubMed
20) Chee KH, Azman W. Prevalence and outcome of peripartum cardiomyopathy in Malaysia. Int J Clin Pract. 2009 ; 63 : 722-5.
PubMed
21) Pandit V, Shetty S, Kumar A, et al. Incidence and outcome of peripartum cardiomyopathy from a tertiary hospital in South India. Trop Doct. 2009 ; 39 : 168-9.
 
22) Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM) : EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017 ; 19 : 1131-41.
 
23) Sliwa K, Hilfiker-Kleiner D, Mebazaa A, et al. EURObservational Research Programme : a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail. 2014 ; 16 : 583-91.
 
24) Ersboll AS, Johansen M, Damm P, et al. Peripartum cardiomyopathy in Denmark : a retrospective, population-based study of incidence, management and outcome. Eur J Heart Fail. 2017 ; 19 : 1712-20.
 
25) Barasa A, Rosengren A, Sandstrom TZ, et al. Heart failure in late pregnancy and postpartum : incidence and long-term mortality in Sweden from 1997 to 2010. J Card Fail. 2017 ; 23 : 370-8.
PubMed
26) Sebillotte CG, Deligny C, Hanf M, et al. Is African descent an independent risk factor of peripartum cardiomyopathy? Int J Cardiol. 2010 ; 145 : 93-4.
PubMed
27) Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 ; 80 : 1602-6.
 
28) Sagy I, Salman AA, Kezerle L, et al. Peripartum cardiomyopathy is associated with increased uric acid concentrations : A population based study. Heart Lung. 2017 ; 46 : 369-74.
PubMed
29) Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis. 2007 ; 17 : 228-33.
 
30) Cenac A, Djibo A. Postpartum cardiac failure in Sudanese-Sahelian Africa : clinical prevalence in western Niger. Am J Trop Med Hyg. 1998 ; 58 : 319-23.
 
31) Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy : experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct. 1995 ; 25 : 118-23.
 
32) Suliman A. The state of heart disease in Sudan. Cardiovasc J Afr. 2011 ; 22 : 191-6.
PubMed
33) Gentry MB, Dias JK, Luis A, et al. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010 ; 55 : 654-9.
PubMed
34) Horne BD, Rasmusson KD, Alharethi R, et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011 ; 4 : 359-66.
PubMed
35) Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 ; 366 : 619-28.
PubMed
36) van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010 ; 121 : 2169-75.
PubMed
37) Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010 ; 121 : 2176-82.
PubMed
38) Karaye KM, Yahaya IA, Lindmark K, et al. Serum selenium and ceruloplasmin in nigerians with peripartum cardiomyopathy. Int J Mol Sci. 2015 ; 16 : 7644-54.
PubMed
39) Fillmore SJ, Parry EH. The evolution of peripartal heart failure in Zaria, Nigeria. Some etiologic factors. Circulation. 1977 ; 56 : 1058-61.
PubMed
40) Sanderson JE, Adesanya CO, Anjorin FI, et al. Postpartum cardiac failure--heart failure due to volume overload? Am Heart J. 1979 ; 97 : 613-21.
PubMed
41) Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000 ; 283 : 1183-8.
PubMed
42) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-78.
 
43) Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation. 2005 ; 111 : 2050-5.
 
44) McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America : results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 ; 66 : 905-14.
PubMed
45) Tanaka H, Katsuragi S, Osato K, et al. The increase in the rate of maternal deaths related to cardiovascular disease in Japan from 1991-1992 to 2010-2012. J Cardiol. 2017 ; 69 : 74-8.
PubMed
46) Dhesi S, Savu A, Ezekowitz JA, et al. Association between diabetes during pregnancy and peripartum cardiomyopathy : a population-level analysis of 309,825 women. Can J Cardiol. 2017 ; 33 : 911-7.
PubMed
47) Isogai T, Kamiya CA. Worldwide incidence of peripartum cardiomyopathy and overall maternal mortality. Int Heart J. 2019. https://doi.org/10.1536/ihj.18-729 [Epub ahead of print]
 

第IV章 リスク因子

P.16 掲載の参考文献
1) Gofton EN, Capewell V, Natale R, et al. Obstetrical intervention rates and maternal and neonatal outcomes of women with gestational hypertension. Am J Obstet Gynecol. 2001 ; 185 : 798-803.
PubMed
2) Barton JR, O'brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term : progression and outcome. Am J Obstet Gynecol. 2001 ; 184 : 979-83.
PubMed
3) Villar J, Carroli G, Wojdyla D, et al. World Health Organization Antenatal Care Trial Research Group. Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent condition? Am J Obstet Gynecol. 2006 ; 194 : 921-31.
PubMed
4) Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy. Hypertens Res. 2017 ; 20 : 213-20.
 
5) 日本妊娠高血圧学会. 妊娠高血圧症候群 新定義・分類 運用上のポイント. 東京 : メジカルビュー社 ; 2019.
 
6) Roberts JM. Preeclampsia : what we know and what we do not know. Semin Perinatol. 2000 ; 24 : 24-8.
PubMed
7) Pijnenborg R, Anthony J, Davey DA, et al. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynecol. 1991 ; 98 : 648-55.
 
8) Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia : the "chicken-and-egg" question. Endocrinology. 2004 ; 145 : 4835-7.
PubMed
9) Nagamatsu T, Fujii T, Kusumi M, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen : an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology. 2004 ; 145 : 4838-45.
PubMed
10) Khaliq A, Dunk C, Jiang J, et al. Hypoxia down-regulates placenta growth factor, whereas fetal growth restriction up-regulates placenta growth factor expression : molecular evidence for "placental hypoxia" in intrauterine growth restriction. Lab Invest. 1999 ; 79 : 151-70.
PubMed
11) Caniggia I, Grisaru-Gravnosky S, Kuliszewsky M, et al. Inhibition of TGF-beta 3 restores the invasive capability of extravillous trophoblasts in preeclamptic pregnancies. J Clin Invest. 1999 ; 103 : 1641-50.
PubMed
12) Gilbert JS, Gilbert SA, Arany M, et al. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension. 2009 ; 53 : 399-403.
PubMed
13) Gu Y, Lewis DF, Wang Y. Placental productions and expression of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2008 ; 93 : 260-6.
PubMed
14) Wang A, Rana S, Karumanchi SA. Preeclampsia : the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009 ; 24 : 147-58.
PubMed
15) Ahmed S, Hewett PW, Al-Ani B, et al. Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis. Vasc Cell. 2011 ; 3 : 15.
 
16) Walshe TE, Saint-Geniez M, Maharaji AS, et al. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One. 2009 ; 4 : e5149.
 
17) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-78.
 
18) Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016 ; 133 : 1397-409.
PubMed
19) Bello N, Rendon IS, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy : a systematic review and meta-analysis. J Am Coll Cardiol. 2013 ; 62 : 1715-23.
PubMed
20) Kao DP, Hsich E, Lindenfeld J. Characteristics, adverse events, and racial differences among delivering mothers with peripartum cardiomyopathy. JACC Heart Fail. 2013 ; 1 : 409-16.
PubMed
21) Fong A, Chau CT, Pan D, et al. Clinical morbidities, trends, and demographics of eclampsia : a population-based study. Am J Obstet Gynecol. 2013 ; 209 : 229. e1-7.
 
22) Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States : a nationwide population-based study. J Am Heart Assoc. 2014 ; 3 : e001056.
PubMed
23) Dennis AT, Solnordal CB. Acute pulmonary oedema in pregnant women. Anaesthesia. 2012 ; 67 : 646-59.
PubMed
24) Friedman SA, Taylor RN, Roberts JM. Pathophysiology of preeclampsia. Clin Perinatol. 1991 ; 18 : 661-82.
PubMed
25) Granger JP, Alexander BT, Llinas MT, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001 ; 38 : 718-22.
PubMed
26) Ntusi NB, Badri M, Gumedze F, et al. Pregnancy associated heart failure : a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. PLoS One. 2015 ; 10 : e0133466.
PubMed
27) Melchiorre K, Sutherland GR, Baltabaeva A, et al. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension. 2011 ; 57 : 85-93.
PubMed
28) Melchiorre K, Sutherland GR, Liberati M, et al. Preeclampsia is associated with persistent postpartum cardiovascular impairment. Hypertension. 2011 ; 58 : 709-15.
PubMed
29) Shahul S, Rhee J, Hacker MR, et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction : a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging. 2012 ; 5 : 734-9.
PubMed
30) Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012 ; 485 : 333-8.
PubMed
31) Arany Z, Foo SY, Ma Y, et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008 ; 451 : 1008-12.
PubMed
32) Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium : the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011 ; 123 : 2856-69.
PubMed
33) Goland S, Modi K, Hatamizadeh P, et al. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J Card Fail. 2013 ; 19 : 214-8.
 
34) Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003 ; 111 : 649-58.
PubMed
35) Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy : results of the multicenter IPAC study. JACC Heart Fail. 2016 ; 4 : 380-8.
PubMed
P.20 掲載の参考文献
1) 厚生労働省. 平成28年 (2016) 人口動態統計 (確定数). 2017. https://www.e-stat.go.jp/dbview?sid=0003214693
 
2) Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006 ; 368 : 687-93.
PubMed
3) Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006 ; 97 : 1765-8.
PubMed
4) Arany Z, Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016 ; 133 : 1397-409.
PubMed
5) Practice Committee of American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy : an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril. 2012 ; 97 : 825-34.
 
6) Chasen ST, Chervenak FA. Twin pregnancy : prenatal issues. Post TW, ed. UpToDate. Waltham : UpToDate Inc. http://www.uptodate.com (Accessed on January 15, 2018.)
 
7) Foley MR. Maternal adaptations to pregnancy : Cardiovascular and hemodynamic changes. Post TW, ed. UpToDate. Waltham : UpToDate Inc. http://www.uptodate.com (Accessed on January 15, 2018.)
 
8) 班長 丹羽公一郎. 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告) 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2010年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2010niwa.h.pdf
 
9) Kametas NA, McAuliffe F, Krampl E, et al. Maternal cardiac function in twin pregnancy. Obstet Gynecol. 2003 ; 102 : 806.
PubMed
10) Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking : systematic review of controlled studies. Br Med J. 2005 ; 330 ; 7491 : 565-7.
 
P.22 掲載の参考文献
1) Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation. 2005 ; 111 : 2050-5.
 
2) Regitz-Zagrosek V, Lundqvist CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy : the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32 : 3147-97.
 
3) Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006 ; 368 : 687-93.
PubMed
4) Abboud J, Murad Y, Chen-Scarabelli C, et al. Peripartum cardiomyopathy : a comprehensive review. Int J Cardiol. 2007 ; 118 : 295-303.
PubMed
5) Lam F, Gill P. β-Agonist tocolytic therapy. Obstet Gynecol Clin N Am. 2005 ; 32 : 457-84.
 
6) Lampert MB, Hibbard J, Weinert L, et al. Peripartum heart failure associated prolonged tocolytic therapy. Am J Obstet Gynecol. 1993 ; 168 : 493-5.
PubMed
7) de Heus R, Mol BW, Erwich JJHM, et al. Adverse drug reactions to tocolytic treatment for preterm labor : prospective cohort study. BMJ. 2009 ; 338 : b744.
PubMed
8) NICE Guideline 25, Methods, evidence and recommendations. November 2015. https://www.nice.org.uk/guidance/ng25/evidence/full-guideline-2176838029
 
9) Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 ; 80 : 1602-6.
 
10) Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971 ; 44 : 1053-61.
PubMed
11) Goland S, Modi K, Bitar F, et al. Clinicla profile and predictors of complications in peripartum cardiomyopathy. J Cardiac Fail. 2009 ; 15 : 645-50.
 
12) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders-results from the Japanese nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
13) キッセイ薬品工業. 欧州における短時間作用型β刺激薬に対する措置ならびに日欧におけるリトドリン (ウテメリン製剤) の使用方法, 有効性及び安全性の情報について. 2014. http://di.kissei.co.jp/vcms_lf/re245001.pdf
 
P.24 掲載の参考文献
1) Demakis JG, Rahimtoola SH. Peripartum Cardiomyopathy. Circulation. 1971 ; 44 : 964-8.
PubMed
2) Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971 ; 44 : 1053-61.
PubMed
3) Fett JD, Carraway RD, Dowell DL, et al. Peripartum cardiomyopathy in the Hospital Albert Schweitzer District of Haiti. Am J Obstet Gynecol. 2002 ; 186 : 1005-10.
 
4) Fett JD, Christile LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 ; 80 : 1602-6.
 
5) Fett JD, Carraway RD, Perry H, et al. Emerging insights into peripartum cardiomyopathy. J Health Popul Nutr. 2003 ; 21 : 1-7.
PubMed
6) Ntusi NB, Badri M, Gumedze F, et al. Pregnancy-associated heart failure : a comparison of clinical presentation and outcome between hypertensive heart failure of pregnancy and idiopathic peripartum cardiomyopathy. PLoS One. 2015 ; 10 : e0133466.
PubMed
7) Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy : a systematic review. Int J Cardiol. 2009 ; 131 : 168-79.
PubMed
8) Prasad GS, Bhupali A, Prasad S, et al. Peripartum cardiomyopathy-case series. Indian Heart J. 2014 ; 66 : 223-6.
PubMed
9) Mandal D, Mandal S, Mukherjee D, et al. Pregnancy and subsequent pregnancy outcomes in peripartum cardiomyopathy. J Obstet Gynaecol Res. 2011 ; 37 : 222-7.
PubMed
10) Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006 ; 152 : 509-13.
PubMed
11) McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America : results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 ; 66 : 905-14.
PubMed
12) Keogh AM, Freund J, Baron DW, et al. Predicts of prognosis in patients with peripartum cardiomyopathy. Am J Cardiol. 1988 ; 61 : 418-22.
PubMed
13) Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy : inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006 ; 27 : 441-6.
PubMed
14) Brar SS, Khan SS, Sandhu GK, et al. Incidence, Mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007 ; 100 : 302-4.
PubMed
15) Krishnamoorthy P, Garg J, Palaniswamy C, et al. Epidemiology and outcomes of peripartum cardiomyopathy in the United States : findings from the Nationwide Inpatient Sample. J Cardiovasc Med. 2016 ; 17 : 756-61.
 
16) Afana M, Brinjikji W, Kao D, et al. Characteristics and in-hospital outcomes of peripartum cardiomyopathy diagnosed during delivery in the United States from the Nationwide Inpatient Sample (NIS) database. J Card Fail. 2016 ; 22 : 512-9.
PubMed
17) Isogai T, Matsui H, Tanaka H, et al. In-hospital management and outcomes in patients with peripartum cardiomyopathy : a descriptive study using a national inpatient database in Japan. Heart Vessels. 2017 ; 32 : 944-51.
PubMed
18) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -results from the Japanese Nationwide survey of peripartum cardiomyopathy-. Circ J. 2011 ; 75 : 1975-81.
PubMed
19) Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation. 2005 ; 111 : 2050-5.
 
20) Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy : analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol. 2000 ; 35 : 701-5.
PubMed
21) Bhattacharyya A, Basra SS, Sen P, et al. Peripartum cardiomyopathy : a review. Tex Heart Inst J. 2012 ; 39 : 8-16.
PubMed
22) Libhaber E, Sliwa K, Bachelier K, et al. Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. Int J Cardiol. 2015 ; 190 : 376-82.
PubMed
23) Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009 ; 15 : 645-50.
PubMed
24) Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, et al. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support. Data from the Interagency Registry for Mechanically Assisted Circulatory Support. Circ Heart Fail. 2014 ; 7 : 300-9.
PubMed
25) Matthews TJ, Hamilton BE. First births to older women continue to rise. NCHS Data Brief. 2014 ; 152 : 1-8.
PubMed
26) Statistics Bureau, Ministry of Internal Affairs and Communications. Statistical handbook of Japan. http://www.stat.go.jp/data/handbook/index.htm, accessed May 25, 2018.
 
27) Whitehead SJ, Berg CJ, Chang J, et al. Pregnancy-related mortality due to cardiomyopathy : United States, 1991-1997. Obstet Gynecol. 2003 ; 102 : 1326-31.
PubMed
28) Tanaka H, Katsuragi S, Osato K, et al. The increase in the rate of maternal deaths related to cardiovascular disease in Japan from 1991-1992 to 2010-2012. J Cardiol. 2017 ; 69 : 74-8.
PubMed
29) Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006 ; 97 : 1765-8.
PubMed
30) Reynolds MA, Schieve LA, Martin JA, et al. Trends in multiple births conceived using assisted reproductive technology, United States, 1997-2000. Pediatrics. 2003 ; 111 : 1159-62.
PubMed
31) Kushnir VA, Barad DH, Albertini DF, et al. Systematic review of worldwide trends in assisted reproductive technology 2004-2013. Reprod Biol Endocrinol. 2017 ; 15 : 6.
PubMed
32) Blazquez A, Garcia D, Rodriguez A, et al. Is oocyte donation a risk factor for preeclampsia? A systematic review and meta-analysis. J Assist Reprod Genet. 2016 ; 33 : 855-63.
PubMed
33) Levron Y, Dviri M, Segol I, et al. The 'immunologic theory' of preeclampsia revisited : a lesson from donor oocyte gestations. Am J Obstet Gynecol. 2014 ; 211 : 383.
 
34) Shani H, Kuperstein R, Berlin A, et al. Peripartum cardiomyopathy-risk factors, characteristics and long-term follow-up. J Perinat Med. 2015 ; 43 : 95-101.
PubMed

第V章 病因

P.30 掲載の参考文献
1) 班長 山科章. 循環器病の診断と治療に関するガイドライン (2011-2012年度合同研究班報告). 血管機能の非侵襲的評価法に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2013_yamashina_h.pdf
 
2) Weissgerber TL, Milic NM, Milin-Lazovic JS, et al. Impaired Flow-mediated dilation before, during, and after preeclampsia : a systematic review and meta-analysis. Hypertension. 2016 ; 67 : 415-23.
PubMed
3) Mahendru AA, Everett TR, Wilkinson IB, et al. A longitudinal study of maternal cardiovascular function from preconception to the postpartum period. J Hypertens. 2014 ; 32 : 849-56.
 
4) Fukushima T, Eguchi K, Ohkuchi A, et al. Changes in central hemodynamics in women with hypertensive pregnancy between before and after delivery. J Clin Hypertens (Greenwich). 2016 ; 18 : 329-36.
PubMed
5) Stanhewicz AE, Jandu S, Santhanam L, et al. Increased angiotensin II sensitivity contributes to microvascular dysfunction in women who have had preeclampsia. Hypertension. 2017 ; 70 : 382-9.
PubMed
P.33 掲載の参考文献
1) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders : results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
2) Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007 ; 100 : 302-4.
PubMed
3) Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy : incidence, predictors, and outcomes. Obstet Gynecol. 2011 ; 118 : 583-91.
PubMed
4) Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy : an ominous diagnosis. Am J Obstet Gynecol. 1997 ; 176 : 182-8.
PubMed
5) Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy : experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Tropical Doctor. 1995 ; 25 : 118-23.
 
6) Fett JD, Christie LG, Carraway RD, et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005 ; 80 : 1602-6.
 
7) van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010 ; 121 : 2169-75.
PubMed
8) Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010 ; 121 : 2176-82.
PubMed
9) Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016 ; 374 : 233-41.
PubMed
10) Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 ; 366 : 619-28.
PubMed
11) Norton N, Li D, Rampersaud E, et al. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet. 2013 ; 6 : 144-53.
PubMed
12) Tobita T, Nomura S, Fujita T, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. Sci Rep. 2018 ; 8 : 1998.
PubMed
13) 日本医学会. 医療における遺伝学的検査・診断に関するガイドライン. 2011. http://jams.med.or.jp/guideline/genetics-diagnosis.pdf
 
14) 文部科学省, 厚生労働省, 経済産業省. ヒトゲノム・遺伝子解析研究に関する倫理指針. 2014. http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/sisin1.pdf
 
15) Mestroni L, Krajinovic M, Severini GM, et al. Familial dilated cardiomyopathy. Br Heart J. 1994 ; 72 : S35-41.
PubMed
16) Toib A, Grange DK, Kozel BA, et al. Distinct clinical and histopathological presentations of Danon cardiomyopathy in young women. J Am Coll Cardiol. 2010 ; 55 : 408-10.
PubMed
17) Davies JE, Winokur TS, Aaron MF, et al. Cardiomyopathy in a carrier of Duchenne's muscular dystrophy. J Heart Lung Transplant. 2001 ; 20 : 781-4.
 
18) Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA. 1996 ; 275 : 1335-8.
 
19) Cheng VE, Prior DL. Peripartum cardiomyopathy in a previously asymptomatic carrier of Duchenne muscular dystrophy. Heart Lung Circ. 2013 ; 22 : 677-81.
 
20) Ahmed A, Spinty S, Murday V, et al. A de-novo deletion of dystrophin provoking severe 'peri-partum cardiomyopathy' : the importance of genetic testing in peripartum cardiomyopathy to uncover female carriers. Int J Cardiol. 2016 ; 203 : 1084-5.
 
21) Soltanzadeh P, Friez MJ, Dunn D, et al. Clinical and genetic characterization of manifesting carriers of DMD mutations. Neuromuscul Disord. 2010 ; 20 : 499-504.
PubMed
22) Giliberto F, Radic CP, Luce L, et al. Symptomatic female carriers of Duchenne muscular dystrophy (DMD) : genetic and clinical characterization. J Neurol Sci. 2014 ; 336 : 36-41.
PubMed
P.36 掲載の参考文献
1) ウィリアムス産科学. 改訂24版. 東京 : 南山堂 ; 2015. p. 1199-201.
 
2) Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States : diagnosis, prognosis, and management. J Am Coll Cardiol. 2011 ; 58 : 659-70.
PubMed
3) Bultmann BD, Klingel K, Nabauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005 ; 193 : 363-5.
PubMed
4) Khosrotehrani K, Johnson KL, Cha DH, et al. Transfer of fetal cells with multilineage potential to maternal tissue. JAMA. 2004 ; 292 : 75-80.
PubMed
5) Ansari AA, Neckelmann N, Wang YC, et al. Immunologic dialogue between cardiac myocytes, endothelial cells, and mononuclear cells. Clin Immunol Immunopathol. 1993 ; 68 : 208-14.
PubMed
6) Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000 ; 283 : 1183-8.
PubMed
7) Arany Z, Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016 ; 133 : 1397-409.
PubMed
8) Kara RJ, Bolli P, Karakikes I, et al. Fetal cells traffic to injured maternal myocardium and undergo cardiac differentiation. Circ Res. 2012 ; 110 : 82-93.
PubMed
9) Geva T, Mauer MB, Striker L, et al. Effects of physiologic load of pregnancy on left ventricular contractility and remodeling. Am Heart J. 1997 ; 133 : 53-9.
PubMed
10) Homans DC. Peripartum cardiomyopathy. N Engl J Med. 1985 ; 312 : 1432-7.
PubMed
11) Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007 ; 128 : 589-600.
PubMed
12) Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013 ; 123 : 2143-54.
PubMed
13) Leanos-Miranda A, Marquez-Acosta J, Cardenas-Mondragon GM, et al. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab. 2008 ; 93 : 2492-9.
PubMed
14) Nakajima R, Ishida M, Kamiya C, et al. Elevated vasoinhibin derived from prolactin and cathepsin D activities in sera of patients with preeclampsia. Hypertens Res. 2015 ; 38 : 899-901.
PubMed
15) Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012 ; 485 : 333-8.
PubMed

第VI章 生理・画像検査

P.41 掲載の参考文献
1) Liu S, Elkayam U, Naqvi TZ. Echocardiography in pregnancy : Part 1. Curr Cardiol Rep. 2016 ; 18 : 92.
PubMed
2) Savu O, Jurcut R, Giusca S, et al. Morphological and functional adaptation of the maternal heart during pregnancy. Circ Cardiovasc imaging. 2012 ; 5 : 289-97.
PubMed
3) Cong J, Fan T, Yang X, et al. Structural and functional changes in maternal left ventricle during pregnancy : a three-dimensional speckle-tracking echocardiography study. Cardiovasc Ultrasound. 2015 ; 13 : 6.
PubMed
4) Khan SG, Melikian N, Mushemi-Blake S, et al. Physiological reduction in left ventricular contractile function in healthy postpartum women : potential overlap with peripartum cardiomyopathy. PloS One. 2016 ; 11 : e0147074.
 
5) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-78.
 
6) Spencer KT, Kimura BJ, Korcarz CE, et al. Focused cardiac ultrasound ; reccomendations from the American Society of Echcardiography. J Am Soc Echocardiogr. 2013 ; 26 : 567-81.
 
7) Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy : National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) work-shop recommendations and review. JAMA. 2000 ; 283 : 1183-8.
 
8) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
9) McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America : results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 ; 66 : 905-14.
PubMed
10) Blauwet LA, Delgado-Montero A, Ryo K, et al. Right Ventricular function in peripartum cardiomyopathy at presentation is associated with subsequent left ventricular recovery and clinical outcomes. Circ Heart Fail. 2016 ; 9 : e002756.
 
11) Briasoulis A, Mocanu M, Marinescu K, et al. Longitudinal systolic strain profiles and outcomes in peripartum cardiomyopathy. Echocardiography. 2016 ; 33 : 1354-60.
PubMed
12) Nishi I, Ishimitsu T, Ishizu T, et al. Peripartum cardiomyopathy and biventricular thrombi. Circ J. 2002 ; 66 : 863-5.
PubMed
13) Shimamoto T, Marui A, Oda M, et al. A case of peripartum cardiomyopathy with recurrent left ventricular apical thrombus. Circ J. 2008 ; 72 : 853-4.
 
P.44 掲載の参考文献
1) Givertz MM. Cardiology patient page : peripartum cardiomyopathy. Circulation. 2013 ; 127 : e622-6.
PubMed
2) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-78.
 
3) Duran N, Gunes H, Duran I, et al. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet. 2008 ; 101 : 137-40.
PubMed
4) Tibazarwa K, Sliwa K. Peripartum cardiomyopathy in Africa : challenges in diagnosis, prognosis, and therapy. Prog Cardiovasc Dis. 2010 ; 52 : 317-25.
PubMed
5) O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy : clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986 ; 8 : 52-6.
PubMed
6) Abboud J, Murad Y, Chen-Scarabelli C, et al. Peripartum cardiomyopathy : a comprehensive review. Int J Cardiol. 2007 ; 118 : 295-303.
PubMed
7) Brown CS, Bertolet BD. Peripartum cardiomyopathy : a comprehensive review. Am J Obstet Gynecol. 1998 ; 178 : 409-14.
PubMed
8) Tibazarwa K, Lee G, Mayosi B, et al. The 12-lead ECG in peripartum cardiomyopathy. Cardiovasc J Afr. 2012 ; 23 : 322-9.
PubMed
9) Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016 ; 133 : 1397-409.
PubMed
10) Ramaraj R, Sorrell VL. Peripartum cardiomyopathy : causes, diagnosis, and treatment. Cleve Clin J Med. 2009 ; 76 : 289-96.
PubMed
11) Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006 ; 152 : 509-13.
PubMed
12) Isogai T, Matsui H, Tanaka H, et al. In-hospital management and outcomes in patients with peripartum cardiomyopathy : a descriptive study using a national inpatient database in Japan. Heart Vessels. 2017 ; 32 : 944-51.
PubMed
13) Yamada T, McElderry HT, Muto M, et al. Ventricular arrhythmias originating from the epicardial ventricular outflow tract complicated with peripartum cardiomyopathy. J Interv Card Electrophysiol. 2009 ; 25 : 53-7.
PubMed
14) Elkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol. 2014 ; 64 : 1629-36.
PubMed
15) Duncker D, Haghikia A, Konig T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014 ; 16 : 1331-6.
PubMed
16) Duncker D, Westenfeld R, Konrad T, et al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction : a German multi-centre analysis. Clin Res Cardiol. 2017 ; 106 : 582-9.
 
P.49 掲載の参考文献
1) Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971 ; 44 : 964-8.
PubMed
2) Sliwa K, Fett J, Elkayam U, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-77.
 
3) Kramer CM, Barkhausen J, Flamm SD, et al. Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance : board of trustees task force on standardized protocols. J Cardiovase Magn Reson. 2008 ; 10 : 35.
PubMed
4) Semelka RC, Tomei E, Wagner S, et al. Normal left ventricular dimensions and function : interstudy reproducibility of measurements with cine MR imaging. Radiology. 1990 ; 174 : 763-8.
PubMed
5) Lima JA, Jeremy R, Guier W, et al. Accurate systolic wall thickening by nuclear magnetic resonance imaging with tissue tagging : correlation with sonomicrometers in normal and ischemic myocardium. J Am Coll Cardiol. 1993 ; 21 : 1741-51.
PubMed
6) Pedrizzetti G, Claus P, Kilner PJ, et al. Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use. J Cardiovasc Magn Reson. 2016 ; 18 : 51.
PubMed
7) Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 ; 343 : 1445-53.
PubMed
8) McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003 ; 108 : 54-9.
PubMed
9) Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CEMARC) : a prospective trial. Lancet. 2012 ; 379 : 453-60.
PubMed
10) Abdel-Aty H, Boye P, Zagrosek A, et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis : comparison of different approaches. J Am Coll Cardiol. 2005 ; 45 : 1815-22.
PubMed
11) Yoon YE, Kitagawa K, Kato S, et al. Prognostic value of coronary magnetic resonance angiography for prediction of cardiac events in patients with suspected coronary artery disease. J Am Coll Cardiol. 2012 ; 60 : 2316-22.
PubMed
12) Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification : a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013 ; 15 : 92.
 
13) Nakamori S, Dohi K, Ishida M, et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging. 2018 ; 11 : 48-59.
PubMed
14) Youn JC, Hong YJ, Lee HJ, et al. Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy-a prospective cohort study. Eur Radiol. 2017 ; 27 : 3924-33.
PubMed
15) Ray JG, Vermeulen MJ, Bharatha A, et al. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA. 2016 ; 316 : 952-61.
PubMed
16) European Society of Urogenital Radiology. ESUR Guideline on Contrast Media 9.0. http://www.guerbet.nl/servicematerialen/esur-guidelines-on-contrast-media-v-90.html, accessed May 25, 2018.
 
17) Mouquet F, Lions C, de Groote P, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol. 2008 ; 18 : 2765-9.
PubMed
18) Renz DM, Rottgen R, Habedank D, et al. New insights into peripartum cardiomyopathy using cardiac magnetic resonance imaging. Rofo. 2011 ; 183 : 834-41.
PubMed
19) Arora NP, Mohamad T, Mahajan N, et al. Cardiac magnetic resonance imaging in peripartum cardiomyopathy. Am J Med Sci. 2014 ; 347 : 112-7.
PubMed
20) Haghikia A, Rontgen P, Vogel-Claussen J, et al. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy : a cardiovascular magnetic resonance study. ESC Heart Fail. 2015 ; 2 : 139-49.
PubMed
21) Schelbert EB, Elkayam U, Cooper LT, et al. Investigations of Pregnancy Associated Cardiomyopathy (IPAC) investigators. Myocardial damage detected by late gadolinium enhancement cardiac magnetic resonance is uncommon in peripartum cardiomyopathy. J Am Heart Assoc. 2017 ; 6 : e005472.
PubMed

第VII章 病理組織学的診断

P.53 掲載の参考文献
1) Ciccone MM, Dentamaro I, Carbonara S, et al. Fulminant peripartum myocarditis associated with sudden cardiac death : a case report. Cardiovasc Pathol. 2016 ; 25 : 87-9.
PubMed
2) O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy : clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol. 1986 ; 8 : 52-6.
PubMed
3) Rizeq MN, Rickenbacher PR, Fowler MB, et al. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol. 1994 ; 74 : 474-7.
PubMed
4) 班長 和泉徹. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版) http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf
 
5) Aretz HT. Myocarditis : the Dallas Criteria. Hum Pathol. 1987 ; 18 : 619-24.
PubMed
6) Melvin KR, Richardson PJ, Olsen EG, et al. Peripartum cardiomyopathy due to myocarditis. N Engl J Med. 1982 ; 307 : 731-4.
PubMed
7) Sanderson JE, Olsen EG, Gatei D. Peripartum heart disease : an endomyocardial biopsy study. Br Heart J. 1986 ; 56 : 285-91.
PubMed
8) Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J. 2000 ; 140 : 785-91.
PubMed
9) 班長 友池仁暢. 循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究斑報告). 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2011_tomoike_h.pdf
 

第VIII章 妊産婦における症状・身体所見の診方と検査の進め方

P.60 掲載の参考文献
1) Bauersachs J, Arrigo M, Sliwa K, et al. Current management of patients with severe acute peripartum cardiomyopathy : practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016 ; 18 : 1096-105.
 
2) Sliwa K, Hilfiker-Kleiner D, Mebazaa A, et al. EURObservational Research Programme : a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail. 2014 ; 16 : 583-91.
 
3) Regitz-Zagrosek V, Lundqvist, CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy : the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32 : 3147-97.
 
4) 班長 丹羽公一郎. 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). 心疾患患者の妊娠・出産の適応, 管理に関するガイドライン (2010年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2010niwa.h.pdf
 
5) Thorne SA. Pregnancy in heart disease. Heart. 2004 ; 90 : 450-6.
PubMed
6) 班長 和泉徹. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 急性心不全治療ガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_izumi_h.pdf
 
7) 班長 筒井裕之. 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf
 
8) Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 ; 342 : 1077-84.
PubMed
9) Tibazarwa K, Lee G, Mayosi B, et al. The 12-lead ECG in peripartum cardiomyopathy. Cardiovasc J Afr. 2012 ; 23 : 322-9.
PubMed
10) Kline JA, Williams GW, Hernandez-Nino J. D-dimer concentrations in normal pregnancy : new diagnostic thresholds are needed. Clin Chem. 2005 ; 51 : 825-9.
PubMed
11) Johnson-Coyle L, Jensen L, Sobey A ; American College of Cardiology Foundation ; American Heart Association. Peripartum cardiomyopathy : review and practice guidelines. Am J Crit Care. 2012 ; 21 : 89-98.
 
12) Mayama M, Yoshihara M, Oguchi H, et al. Factors influencing brain natriuretic peptide levels in healthy pregnant women. Int J Cardiol. 2017 ; 228 : 749-53.
PubMed
13) 班長 和泉徹. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf
 
14) 班長 吉田清. 循環器病の診断と治療に関するガイドライン (2009年度合同研究班報告). 循環器超音波検査の適応と判読ガイドライン (2010年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2010yoshida.h.pdf
 
15) Nagueh SF, Smiseth OA, Waggoner AD, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography : an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016 ; 29 : 277-314.
PubMed

第IX章 鑑別診断

P.69 掲載の参考文献
1) Bauersachs J, Arrigo M, Sliwa K, et al. Current management of patients with severe acute peripartum cardiomyopathy : practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016 ; 18 : 1096-105.
 
2) Sliwa K, Hilfiker-Kleiner D, Mebazaa A, et al. EURObservational Research Programme : a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM. Eur J Heart Fail. 2014 ; 16 : 583-91.
 
3) European Society of Gynecology (ESG) ; Association for European Paediatric Cardiology (AEPC) ; German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Torracca L, et al. ESC Committee for Practice Guidelines. ESC Guidelines on the management of cardiovascular diseases during pregnancy : the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32 : 3147-97.
 
4) Satoh H, Sano M, Hayashi H, et al. Pregnancy-related acute myocardial infarction in Japan : a review of epidemiology, etiology and treatment from case reports. Circ J. 2013 ; 77 : 725-33.
PubMed
5) James AH, Jamison MG, Myers ER, et al. Acute myocardial infarction in pregnancy : a United States population-based study. Circulation. 2006 ; 28 ; 113 : 1564-71.
 
6) Fujiwara Y, Yamanaka O, Yamaguchi H, et al. Acute myocardial infarction induced by ergonovine administration for artificially induced abortion. Jpn Heart J. 1993 ; 34 : 803-8.
PubMed
7) Hayashi Y, Ibe T, Ikea U, et al. Postpartum acute myocardial infarction induced by ergonovine administration. Intern Med. 2003 ; 42 : 983-6.
 
8) Yaegashi N, Miura M, Okamura K. Acute myocardial infarction associated with postpartum ergot alkaloid administration. Int J Gynecol Obstet. 1999 ; 64 : 67-8.
 
9) Oei SG, Oei SK, Brolmann HA. Myocardial infarction during nifedipine therapy for preterm labor. N Engl J Med. 1999 ; 340 : 154.
PubMed
10) Chen YC, Chang YM, Hsieh CTC, et al. Acute myocardial infarction during pregnancy. Taiwan J Obstet Gynecol. 2009 ; 48 : 181-5.
PubMed
11) Cade JR, Szarf G, de Siqueira ME, et al. Pregnancy-associated spontaneous coronary artery dissection : insights from a case series of 13 patients. Eur Heart J Cardiovasc Imaging. 2017 ; 18 : 54-61.
PubMed
12) Havakuk O, Goland S, Elkayam, et al. Pregnancy and the risk of spontaneous coronary artery dissection : an analysis of 120 contemporary cases. Circ Cardiovasc Interv. 2017 ; 10 : e004941.
PubMed
13) 班長 安藤太三. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf
 
14) Conti E, Zezza L, Volpe M, et al. Pulmonary embolism in pregnancy. J Thromb Thrombolysis. 2014 ; 37 : 251-70.
PubMed
15) 班長 和泉徹. 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告). 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2009_izumi_h.pdf
 
16) Ukimura A, Izumi T, Matsumori A ; Clinical Research Committee on Myocarditis Associated with 2009 Influenza A (H1N1) Pandemic in Japan organized by Japanese Circulation Society. A national survey on myocarditis associated with the 2009 influenza A (H1N1) pandemic in Japan. Circ J. 2010 ; 74 : 2193-9.
PubMed
17) Ukimura A, Ooi Y, Izumi T, et al. A national survey on myocarditis associated with influenza H1N1 pdm 2009 in the pandemic and postpandemic season in Japan. J Infect Chemother. 2013 ; 19 : 426-31.
 
18) Chan K, Meek D, Chakravorty I. Unusual association of ST-T abnormalities, myocarditis and cardiomyopathy with H1N1 influenza in pregnancy : two case reports and review of literature. J Med Case Rep. 2011 ; 5 : 314-8.
PubMed
19) Ona MA, Bashari DR, Royzman R, et al. A case of fatal fulminant myocarditis presenting as an acute ST-segment elevation myocardial infarction and persistent ventricular tachyarrhythmia associated with influenza A (H1N1) virus in a previously healthy pregnant woman. Cardiology. 2012 ; 123 : 103-7.
 
20) Law WG, Thong BY, Chng HH, et al. Acute lupus myocarditis : clinical features and outcome of an oriental case series. Lupus. 2005 ; 14 : 827-31.
PubMed
21) Matsui S, Yamashita N, Kobayashi M, et al. Effects of pregnancy and delivery on sarcoidosis. JJSOG. 2001 ; 21 : 25-9.
 
22) Wallmuller C, Domanovits H, Laggner AN, et al. Cardiac arrest in a 35-year-old pregnant woman with sarcoidosis. Resuscitation. 2012 ; 83 : e151-2.
 
23) Nagata N, Fukuda A, Ogawa H, et al. Postpartum thyrotoxic crisis diagnosed as Graves' disease : a case report. Adv Obstet Gynecol. 2013 ; 65 : 146-52.
 
24) Nakajima Y, Masaoka N, Sakai M, et al. Pheochromocytoma-related cardiomyopathy during the antepartum period in a preterm pregnant woman. J Obstet Gynaecol Res. 2011 ; 37 : 908-11.
 
25) Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy : pathophysiology, mechanisms, clinical features and management. Int J Cardiol. 2014 ; 172 : 40-6.
PubMed
26) Sag S, Coskun H, Aydinlar A, et al. Inappropriate sinus tachycardia-induced cardiomyopathy during pregnancy and successful treatment with ivabradine. Anatol J Cardiol. 2016 ; 16 : 212-3.
PubMed
27) Szumowski L, Szufladowicz E, Walczak F, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol. 2010 ; 21 : 877-82.
PubMed
28) 吉川勉. たこつぼ症候群 総論. 心臓. 2016 ; 48 : 1120-6.
 
29) Kawai S, Kitabatake A, Tomoike H ; Takotsubo Cardiomyopathy Group. Guidelines for diagnosis of takotsubo (ampulla) cardiomyopathy. Circ J. 2007 ; 71 : 990-2.
PubMed
30) Lyon AR, Bossone E, Schneider B, et al. Current state of knowledge on Takotsubo syndrome : a position statement from the task force on Takotsubo syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016 ; 18 : 8-27.
 
31) Kosuge M, Kimura K. Clinical implications of electrocardiograms for patients with anterior wall ST-segment elevation acute myocardial infarction in the interventional era. Circ J. 2012 ; 76 : 32-40.
 
32) Zorzi A, Baritussio A, Corrado D, et al. Differential diagnosis at admission between Takotsubo cardiomyopathy and acute apical-anterior myocardial infarction in postmenopausal women. Eur Heart J Acute Cardiovasc Care. 2016 ; 5 : 298-307.
PubMed
33) Wittstein IS, Thiemann DR, Champion HC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005 ; 352 : 539-48.
PubMed
34) Ruiz S, Martinez-Marin M, Oros D, et al. Takotsubo cardiomyopathy after cesarean section : a case report and literature review. J Obstet Gynaecol Res. 2017 ; 43 : 392-6.
 

第X章 遺伝学的検査

P.73 掲載の参考文献
1) Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation. 1971 ; 44 : 964-8.
PubMed
2) Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy : clinical characteristics and a comparison between early and late presentation. Circulation. 2005 ; 111 : 2050-5.
 
3) McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomy opathy in North America : results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 ; 66 : 905-14.
 
4) 班長 友池仁暢. 循環器病の診断と治療に関するガイドライン (2009-2010年度合同研究班報告). 拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2011_tomoike_h.pdf
 
5) Horne BD, Rasmusson KD, Alharethi R, et al. Genome-wide significance and replication of the chromosome 12p11.22 locus neart the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet. 2011 ; 4 : 359-66.
 
6) 班長 永井良三. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告). 心臓血管疾患における遺伝学的検査と遺伝カウンセリングに関するガイドライン (2011年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2011_nagai_h.pdf
 
7) van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010 ; 121 : 2169-75.
PubMed
8) Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010 ; 121 : 2176-82.
PubMed
9) Herman DS, Lam L, Taylor MRG, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 ; 366 : 619-28.
PubMed
10) Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016 ; 374 : 233-41.
PubMed
11) Palojoki E, Kaartinen M, Kaaja R, et al. Pregnancy and childbirth in carriers of the lamin A/C-gene mutation. Eur J Heart Fail. 2010 ; 12 : 630-3.
PubMed
12) Gifford RW, August PA, Cunningham G, et al. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000 ; 183 : S1-22.
 
13) Bello N, Rendon ISH, Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy : a systematic review and meta-analysis. J Am Coll Cardiol. 2013 ; 62 : 1715-23.
PubMed
14) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders : results from the Japanese nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
15) Behrens I, Basit S, Lykke JA, et al. Association between hypertensive disorders of pregnancy and later risk of cardiomyopathy. JAMA. 2016 ; 315 : 1026-33.
PubMed
16) Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet. 2010 ; 376 : 631-44.
PubMed
17) 日本妊娠高血圧学会, 編. 妊娠高血圧症候群の診療指針 2015 Best Practice Guide. 東京 : メジカルビュー社 ; 2015.
 
18) Williams PJ, Pipkin FB. The genetics of pre-eclampsia and other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Hynaecol. 2011 ; 25 : 405-17.
 
19) Buurma AJ, Turner RJ, Driessen JHM, et al. Genetic variants in pre-eclampsia : a meta-analysis. Hum Reprod Update. 2013 ; 19 : 289-303.
 
20) Morgan T, Craven C, Nelson L, et al. Angiotensinogen T235 expression is elevated in decidual spiral arteries. J Clin Invest. 1997 ; 100 : 1406-15.
PubMed
21) Sgambati E, Marini M, Zappoli Thyrion GD, et al. VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. BJOG. 2004 ; 111 : 564-70.
PubMed
22) Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012 ; 485 : 333-8.
PubMed
23) Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science. 2000 ; 289 : 119-23.
PubMed
24) 文部科学省, 厚生労働省, 経済産業省. ヒトゲノム・遺伝子解析研究に関する倫理指針. 2014. http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkanboukouseikagakuka/sisin1.pdf
 

第XI章 治療

P.83 掲載の参考文献
1) 日本循環器学会, 日本心不全学会「心不全の定義」2017.
 
2) Mckee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure : the Framingham Heart Study. N Engl J Med. 1971 ; 285 : 1441-6.
PubMed
3) Hoes MF, Van Hagen I, Russo F, et al. Peripartum cardiomyopathy : observational Reseach Program. Neth Heart J. 2014 ; 22 : 396-400.
 
4) Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. RCOG Green Top Guideline. 2015. p. 37a.
 
5) Kelder JC, Cowie MR, McDonagh TA, et al. Quantifying the added value of BNP in suspected heart failure in general practice : an individual patient data meta-analysis. Heart. 2011 ; 97 : 959-63.
PubMed
6) Gustafsson F, Steensgaard-Hansen F, Badskjaer J, et al. Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail. 2005 ; 11 : 15-S20.
 
7) 班長 筒井裕之. 日本循環器学会/日本心不全学会合同ガイドライン. 急性・慢性心不全診療ガイドライン (2017年改訂版). http://www.j-circ.or.jp/guideline/pdf/JCS2017_tsutsui_h.pdf
 
8) Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol. 2003 ; 41 : 1797-804.
PubMed
9) Stevenson LW. Design of therapy for advanced heart failure. Eur J Heart Fail. 2005 ; 7 : 323-31.
PubMed
10) Matsue Y, Damman K, Voors AA, et al. Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol. 2017 ; 69 : 3042-51.
PubMed
11) O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure : insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999 ; 138 : 78-86.
PubMed
12) De Backer D, Biston P, Devriendt J, et al. SOAP Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010 ; 362 : 779-89.
 
13) Amos AM, Jaber WA, Russell SD, et al. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006 ; 152 : 509-13.
PubMed
14) Yoshikawa T, Baba A, Suzuki M, et al ; for the Keio Interhospital Cardiology Study (KICS) Group. Effectiveness of carvedilol alone versus carvedilol+pimobendan for severe congestive heart failure. Am J Cardiol. 2000 ; 85 : 1495-7.
PubMed
15) Stevenson LW, Massie BM, Francis G. Optimizing therapy for complex or refractory heart failure : a management algorithm. Am Heart J. 1998 ; 135 : S293-309.
PubMed
16) Bristow MR, Gilbert EM, Abraham WT, et al ; for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996 ; 94 : 2807-16.
PubMed
17) Easterling TR, Brateng D, Schmucker B, et al. Prevention of preeclampsia : a randomized trial of atenorol in hyper dynamic patients before onset of hypertension. Obstet Gynecol. 1999 ; 93 : 725-33.
 
18) Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999 ; 100 : 2312-8.
 
19) Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 ; 341 : 709-17.
 
20) Pitt B, Remme W, Zannad F, et al ; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348 : 1309-21.
 
21) Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011 ; 364 : 11-21.
PubMed
22) Norman JC, Cooley DA, Igo SR, et al. Prognostic indices for survival during postcardiotomy intra-aortic balloon pumping. Methods of scoring and classification, with implications for left ventricular assist device utilization. J Thorac Cardiovasc Surg. 1977 ; 74 : 709-20.
PubMed
23) 班長 許俊鋭. 日本循環器学会/日本心臓血管外科学会合同ガイドライン (2011-2012年度合同研究班報告). 重症心不全に対する植込型補助人工心臓治療ガイドライン. http://www.j-circ.or.jp/guideline/pdf/JCS2013_kyo_h.pdf
 
24) Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014 ; 130 : 94-125.
PubMed
25) Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy. J Am Coll Cardiol. 2013 ; 61 : 1323-73.
 
26) 2008 Guidelines for Device-Based Therapy. http://circ.ahajournals.org/content/117/21/e350
 
27) Duncker D, Haghikia A, Konig T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014 ; 16 : 1331-6.
PubMed
28) Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009 ; 15 : 645-50.
PubMed
29) Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States : diagnosis, prognosis, and management. J Am Coll Cardiol. 2011 ; 58 : 659-70.
PubMed
30) 班長 庭野慎一. 着用型自動除細動器 (WCD) の臨床使用に関するステートメント (2015年4月改訂). http://new.jhrs.or.jp/pdf/guideline/statement201505_01.pdf
 
31) Rasmusson KD, Stehlik J, Brown R, et al. Long-term outcomes of cardiac transplantation for peri-partum cardiomyopathy : a multi institutional analysis. J Heart Lung Transplant. 2007 ; 26 : 1097-104.
 
32) Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy : post-transplant outcomes from the United Network for organ sharing database. J Heart Lung Transplant. 2012 ; 31 : 180-6.
 
33) Steer PJ, Gatzoulis MA. Heart disease and pregnancy. Management of cardiomyopathies in pregnancy. 2nd ed. Cambridge : Cambridge University Press ; 2016. p. 165.
 
34) Safirstein JG, Ro AS, Grandhi S, et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012 ; 154 : 27-31.
 
35) Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy : practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 10.1002/ejhf. 1178, 2018 e-pub ahead of print
 
P.87 掲載の参考文献
1) Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy : a proof-of-concept pilot study. Circulation. 2010 ; 121 : 1465-73.
PubMed
2) Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy : a multicentre randomized study. Eur Heart J. 2017 ; 35 : 2671-9.
PubMed
3) McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America : Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 ; 66 : 905-14.
PubMed
4) Kamiya CA, Yoshimatsu J, Ikeda T. Effects of anti-prolactin therapy and prolactin fragment values from a nationwide prospective study on peripartum cardiomyopathy in Japan. Circ J. 2015 ; 79 (Supple I) : I-623.
 
5) Biteker M, Duran NE, Kaya H, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol. 2011 ; 100 : 571-7.
PubMed
6) Sliwa K, Skudicky D, Candy G, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002 ; 4 : 305-9.
PubMed
7) Desplantie O, Tremblay-Gravel M, Avram R, et al. The medical treatment of new-onset peripartum cardiomyopathy : a systematic review of prospective studies. Can J Cardiol. 2015 ; 31 : 1421-6.
PubMed

第XII章 予後

P.90 掲載の参考文献
1) Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000 ; 342 : 1077-84.
PubMed
2) Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016 ; 374 : 233-41.
PubMed
3) Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016 ; 133 : 1397-409.
PubMed
4) Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders : results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J. 2011 ; 75 : 1975-81.
PubMed
5) Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol. 2013 ; 108 : 366.
 
6) McNamara DM, Elkayam U, Alharethi R, et al. Clinical outcomes for peripartum cardiomyopathy in North America : results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015 ; 66 : 905-14.
PubMed
7) Sliwa K, Forster O, Libhaber E, et al. Peripartum cardiomyopathy : inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J. 2006 ; 27 : 441-6.
PubMed
8) Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet. 2006 ; 368 : 687-93.
PubMed
9) Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail. 2009 ; 15 : 645-50.
PubMed
10) Biteker M, Ilhan E, Biteker G, et al. Delayed recovery in peripartum cardiomyopathy : an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012 ; 14 : 895-901.
PubMed
11) Blauwet LA, Libhaber E, Forster O, et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart. 2013 ; 99 : 308-13.
PubMed
12) Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011 ; 17 : 426-30.
PubMed
13) Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006 ; 152 : 509-13.
PubMed
14) Bello N, Hurtado Rendon I, Arany Z. The relationship between preeclampsia and peripartum cardiomyopathy : A systematic review and meta-analysis. J Am Coll Cardiol. 2013 ; 62 : 1715-23.
 
15) Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy : a systematic review. Int J Cardiol. 2009 ; 131 : 168-79.
PubMed
16) van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014 ; 35 : 2165-73.
PubMed
17) Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med. 2012 ; 366 : 619-28.
PubMed
18) Kamiya CA, Yoshimatsu J, Ikeda T. Peripartum cardiomyopathy from a genetic perspective. Circ J. 2016 ; 80 : 1684-8.
PubMed
19) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767-78.
 
20) McNamara DM, Starling RC, Cooper LT, et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy : results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy) -2 study. J Am Coll Cardiol. 2011 ; 58 : 1112-8.
PubMed
P.94 掲載の参考文献
1) Ersboll AS, Damm P, Gustafsson F, et al. Peripartum cardiomyopathy : a systematic literature review. Acta Obstet Gynecol Scand. 2016 ; 95 : 1205-19.
PubMed
2) Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartumcardiomyopathy. N Engl J Med. 2001 ; 344 : 1567-71.
 
3) Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet. 2010 ; 109 : 34-6.
PubMed
4) Elkayam U. Risk of subsequent pregnancy in women with a history of peripartumcardiomyopathy. J Am Coll Cardiol. 2014 ; 64 : 1629-36.
 
5) Hilfiker-Kleiner D, Haghikia A, Nonhoff J, et al. Peripartum cardiomyopathy : current management and future perspectives. Eur Heart J. 2015 ; 36 : 1090-7.
PubMed
6) Hilfiker-Kleiner D, Haghikia A, Masuko D, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. Eur J Heart Fail. 2017 ; 12 : 1723-8.
PubMed
7) Codsi E, Rose CH, Blauwet LA. Subsequent pregnancy outcomes in patients with peripartum cardiomyopathy. Obstet Gynecol. 2018 ; 131 : 322-7.
PubMed
8) Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006 ; 32 : 75-81.
PubMed
9) Regitz-Zagrosek V, Lundqvist, CB, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy : the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011 ; 32 : 3147-97.
 
10) Bozkurt B, Colvin M, Cook J, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies : a scientific statement from the American Heart Association. Circulation. 2016 ; 134 : e579-646.
PubMed
11) Goland S, Weinstein JM, Zalik A, et al. Angiogenic imbalance and residual myocardial injury in recovered peripartum cardiomyopathy patiets. Circ Heart Fail. 2016 ; 9 : e003349.
 
12) Damp J, Givertz MM, Semigran M, et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy. results of the multicenter IPAC Study. JACC Heart Failure. 2016 ; 4 : 380-8.
PubMed
13) Arora NP, Mohamad T, Mahajan N, et al. Cardiac magnetic resonance imaging in peripartum cardiomyopathy. Am J Med Sci. 2014 ; 347 : 112-7.
PubMed
14) Haghikia A, Rontgen P, Vogel-Claussen J, et al. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy : a cardiovascular magnetic resonance study. ESC Heart Failure. 2015 ; 2 : 139-49.
PubMed
15) Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetilogy, diagnosis, management, and therapy of peripartum cardiomyopathy : a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010 ; 12 : 767.
 
16) van Spaendonck-Zwarts KY, van Tintelen, JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010 ; 121 : 2169-75.
PubMed
17) Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010 ; 121 : 2176-82.
PubMed
18) van Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, et al. Titin genemutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014 ; 35 : 2165-73.
 
19) Ware JS, Li J, Mazaika E, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016 ; 374 : 233-41.
PubMed
20) Rosman L, Salmoirago-Blotcher E, Wuensch KL, et al. Contraception and reproductive counseling in women with peripartum cardiomyopathy. Contraception. 2017 ; 96 : 36-40.
PubMed
21) Koutrolou-Sotiropoulou P, Lima FV, Stergiopoulos K. Quality of life in survivors of peripartum cardiomyopathy. Am J Cardiol. 2016 ; 118 : 258-63.
PubMed
22) Rosman L, Salmoirago-Blotcher E, Cahill J, et al. Depression and health behaviors in women with peripartum cardiomyopathy. Heart & Lung. 2017 ; 46 : 363-8.
PubMed
23) Tepper NK, Paulen ME, Marchbanks PA, et al. Safety of contraceptive use among women with peripartum cardiomyopathy : a systematic review. Contraception. 2010 ; 82 : 95-101.
PubMed

付記 1 ハイリスク妊娠における早期診断法

P.97 掲載の参考文献
1) 国立循環器病研究センター. 周産期心筋症. http://www.ncvc.go.jp/cvdinfo/disease/peripartum-cardiomyopathy.html, accessed May 25, 2018.
 
2) 岸上靖幸, 太田智之, 邨瀬智彦, 他. 産褥性心筋症とその予測. 日本周産期・新生児会誌. 2010 ; 46 : 1297-301.
 
3) 近藤真哉, 吉原雅人, 眞山学徳, 他. 脳性ナトリウム利尿ペプチドによる妊産婦の心機能評価と周産期心筋症発症の予測. 産婦の実際. 2014 ; 63 : 263-71.
 

書評

最近チェックした商品履歴

Loading...